Wintermute Biomedical strengthens its board credentials with the announcement of Prof. Skerritt, former head of Australia's Therapeutic Goods Administration.
Wintermute Biomedical Inc. (USA/Australia), a privately owned, clinical-stage biotechnology company, is pleased to announce the appointment of Prof. John Skerritt AM FTSE as a Non-Executive Director.
Prof. Skerritt is Enterprise Professor in Health Research Impact at the University of Melbourne, and Adjunct Professor in the Faculty of Medicine and Health at the University of Sydney. He has extensive research experience in pharmacology and immunology. Until April 2023, he was Deputy Secretary of the Australian Department of Health and Aged Care, and concomitantly Head of the Therapeutic Goods Administration. He is a member of the Boards of Medicines Australia and AusBiotech, Chair of the Scientific Advisory Council of the UK-based Centre for Innovation in Regulatory Science, and a member of the Board of the Singapore-based Centre for Regulatory Excellence. He also played a major role in advising the Australian government on the establishment of an mRNA vaccines and medicines industry, and in the regulatory approval of vaccines during the SARS-CoV-2 pandemic.
Wintermute Executive Chairman, Mr. Paul Field, commented: “John is an eminent Australian who deeply understands the clinical and regulatory pathway on which we are travelling with Solexan™, our topical antiviral product for the treatment of shingles pain and enhanced lesion healing. We are truly delighted to welcome John to the Board.”
Non-Executive Director, Prof. Skerritt, commented: “I’m pleased to be joining the Board of Wintermute Biomedical at this pivotal time. The Phase 1b ZosterEase trial results were very promising, and the Company now has the opportunity to progress into a Phase II/III randomised, placebo-controlled clinical trial in 2026, and to develop other topical products. I look forward to working closely with the Board, CEO Dr. Tom Rau, and the Management team as we execute on this next phase of growth”.
This announcement is authorised for release by the Board of Directors of Wintermute Biomedical Inc.